Trials Sponsors Conditions Drugs Pricing

Conditions

Cataract Lens Opacities Macular Degeneration

Keywords

Age-Related Macular Degeneration

Outcome Measures

Primary Outcomes (2)

Progression of age-related macular degeneration
Progression of lens opacity (cataract)

Study Arms (4)

1

EXPERIMENTAL

Antioxidants

Dietary Supplement: Antioxidants

2

EXPERIMENTAL

Zinc

Dietary Supplement: Zinc

3

EXPERIMENTAL

Antioxidants and zinc

Dietary Supplement: Antioxidants and zinc

Interventions

AntioxidantsDietary supplement

500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene

ZincDietary supplement

80 milligrams zinc oxide; 2 milligrams of cupric oxide

Eligibility Criteria

Age55 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Men and women between the ages of 55 and 80 years whose macular status ranges from no evidence of AMD in either eye to relatively severe disease with vision loss in one eye but good vision in the fellow eye (20/30 or better) are eligible for the study provided that their ocular media are clear enough to allow good fundus photography.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

National Eye Institute (NEI)
NIHlead
Bausch & Lomb Incorporated
Industrycollaborator

Related Publications (28)

Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001 Nov;132(5):668-81. doi: 10.1016/s0002-9394(01)01218-1.
PMID: 11704028BACKGROUND
Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. Am J Ophthalmol. 2001 Feb;131(2):167-75. doi: 10.1016/s0002-9394(00)00732-7.
PMID: 11228291BACKGROUND

MeSH Terms

Conditions

Macular DegenerationCataract

Interventions

AntioxidantsZinc

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye DiseasesLens Diseases

Intervention Hierarchy (Ancestors)

Biological FactorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesProtective Agents

Study Officials

Emily Y. Chew, MD
National Eye Institute (NEI)
PRINCIPAL INVESTIGATOR

Enrollment

4,757 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: FACTORIAL
Sponsor Type: NIH

Study Record Dates

First Submitted

September 23, 1999

First Posted

September 24, 1999

Study Start

September 1990

Date type not reported

This date has not been verified as actual or estimated.

Age-Related Eye Disease Study (AREDS)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Study Arms (4)

1

2

3

Interventions

Eligibility Criteria

Sponsors & Collaborators

Related Publications (28)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

4

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Study Arms (4)

1

2

3

Interventions

Eligibility Criteria

Sponsors & Collaborators

Related Publications (28)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

4

Source record